Wir sind mit live! Mehr erfahren

Accendra Health

ACH

Börsenwert 18,1 Mio. $

0,2350 USD

-0,0265

10,13 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

0,2499

+0,0149

6,34 %

1 Tag

-10,13 %

5 Tage

-46,59 %

1 Monat

-78,04 %

3 Monate

-93,78 %

6 Monate

-92,94 %

Seit Jahresbeginn

-89,87 %

1 Jahr

-94,88 %

5 Jahre

-99,28 %

10 Jahre

-99,28 %

Profil: Accendra Health Inc is a nationwide provider of products, technology, and services that support health beyond the hospital by connecting patients, providers, and insurers. Through its brands, Apria and Byram Healthcare, the company delivers disposable medical supplies, integrated home healthcare equipment, and related services that help improve health outcomes and quality of life for individuals with chronic, complex, and acute health conditions. Its offerings span diabetes treatment, home respiratory therapy, and obstructive sleep apnea treatment, along with patient support services. The company also supplies a broad range of home medical equipment and patient care products, including ostomy, wound care, urology, and incontinence solutions.

Mitarbeiter: 6.500

Gesundheitswesen Medizinischer Großhandel

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 9,1 %

Neutral 72,7 %

Negativ 18,2 %

Accendra Health Receives Continued Listing Standard Notice from NYSE; Intends to Cure Deficiency and Return to Compliance with NYSE Listing Standard

RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the Company) today announced that on October 6, 2026, it received a notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) notifying the Company that it is not in compliance with the NYSE's continued listing standards because the average closing price of the Company's Class A Common Stock (the “Common Stock”) was less than $1.00 per share over a consecutive 30 trading-day period. The Notice does not result in the im.

Accendra Health Receives Continued Listing Standard Notice from NYSE; Intends to Cure Deficiency and Return to Compliance with NYSE Listing Standard

Zacks Investment Research

New Strong Sell Stocks for October 9th

ACH, ARDX and DPRO have been added to the Zacks Rank #5 (Strong Sell) List on October 9th, 2026.

New Strong Sell Stocks for October 9th

Zacks Investment Research

New Strong Sell Stocks for October 6th

VLVLY, ACH and CCJ have been added to the Zacks Rank #5 (Strong Sell) List on October 6th, 2026.

New Strong Sell Stocks for October 6th

Accendra Health Names Kenneth Gardner-Smith as President and Chief Executive Officer to Lead the Company's Next Chapter of Growth

RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) today named Kenneth Gardner-Smith as the Company's next President and Chief Executive Officer. Gardner-Smith, who has served on the Company's Board of Directors since March 2022, is expected to assume the role early in the fourth quarter 2026. He will succeed Edward A. Pesicka, who announced his intent to retire in August. Gardner-Smith brings deep experience running large-scale patient care operations and guiding.

Accendra Health Names Kenneth Gardner-Smith as President and Chief Executive Officer to Lead the Company's Next Chapter of Growth

Accendra Health Updates on Capital Allocation and CEO Succession Timing Plans

RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health (the “Company”) is providing an update on its capital allocation plans and the timeline for the replacement of its chief executive officer. Given recent market conditions, the Company has determined that it is in the best interest of stakeholders not to put in place an at-the-market issuance program. The program was intended to allow the Company to opportunistically issue modest amounts of equity over time, with the proceeds to be used to reduce o.

Accendra Health Updates on Capital Allocation and CEO Succession Timing Plans

Accendra Health, Inc. (ACH) Q2 2026 Earnings Call Transcript

Accendra Health, Inc. (ACH) Q2 2026 Earnings Call Transcript

Accendra Health, Inc. (ACH) Q2 2026 Earnings Call Transcript

Accendra Health Announces Adoption of Tax Asset Preservation Plan To Protect Long Term Shareholder Value

RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the Company) announced today that its Board of Directors adopted a Section 382 Rights Agreement (the “Tax Asset Preservation Plan”) designed to protect long-term shareholder value by facilitating the Company's ability to preserve its net operating loss carryforwards (“NOLs”) and certain other tax attributes. A company generally experiences an ownership change if the percentage of the value of its stock owned by certain “5-percen.

Accendra Health Announces Adoption of Tax Asset Preservation Plan To Protect Long Term Shareholder Value

Accendra Health Reports Second Quarter 2026 Financial Results

RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the Company) today reported financial results for the second quarter ended June 30, 2026. Unless otherwise noted, the results herein reflect the Company's continuing operations, which represent what was previously the Patient Direct segment and certain functional operations. “Throughout the second quarter, we moved farther along toward the complete separation from Owens & Minor while also putting a large commercial payor exi.

Accendra Health Reports Second Quarter 2026 Financial Results

Accendra Health's Ed Pesicka Announces Intent to Retire; Board of Directors Has Begun Successor Search

RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the Company) today announced that President and Chief Executive Officer Edward A. Pesicka has informed the Board of Directors of his plan to retire by the end of 2026, after more than seven years with the Company. Mr. Pesicka will also retire from the Company's Board of Directors before the end of the year. The Board of Directors maintains a long-standing, robust succession planning process established to address officer success.

Accendra Health's Ed Pesicka Announces Intent to Retire; Board of Directors Has Begun Successor Search

Accendra Health Q2 Preview: Low Expectations Create Opportunity

Accendra Health remains a speculative buy despite recent share declines and sector-driven volatility. ACH's limited exposure to capitated contracts and prudent exit from risky agreements mitigate margin risk seen in peers like AHCO. Balance sheet restructuring has reduced gross borrowings by at least $350 million, extending maturities and enabling future deleveraging.

Accendra Health Q2 Preview: Low Expectations Create Opportunity

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt